Aligos Therapeutics Inc (ALGS) Stock Analysis
Verdict: AVOID
Investment score: 28/100
Analysis as of
Is Aligos Therapeutics Inc stock worth reviewing? The TradeMates thesis
Aligos is a microcap biotech with a broken balance sheet. Despite analyst optimism, the mathematical reality of its cash burn vs. cash on hand makes it a high-risk candidate for immediate dilution or insolvency.
7-factor investment score
- Valuation: 40/100 (weight 20%)
- Financial Health: 10/100 (weight 15%)
- Technical Momentum: 30/100 (weight 15%)
- Earnings Quality: 35/100 (weight 15%)
- Insider Sentiment: 20/100 (weight 10%)
- Analyst Consensus: 75/100 (weight 10%)
- Risk-Adjusted Return: 15/100 (weight 15%)
Aligos Therapeutics Inc opportunities and risks
What speaks for ALGS
- Positive Phase 2a MASH Data
What speaks against ALGS
- Imminent Dilution or Bankruptcy
Peers and competitors
- RLYB
- LITS
- SNSE
- NXTC
- ATRA
Frequently asked questions about Aligos Therapeutics Inc (ALGS)
Is ALGS stock a good investment?
The TradeMates model rates Aligos Therapeutics Inc as AVOID with an investment score of 28/100. Aligos is a microcap biotech with a broken balance sheet. Despite analyst optimism, the mathematical reality of its cash burn vs. cash on hand makes it a high-risk candidate for immediate dilution or insolvency. This is algorithmic model output, not personal investment advice.
Is ALGS stock a buy?
The TradeMates model verdict for ALGS is AVOID with an investment score of 28/100. Treat this as a model signal to review, not a personal buy recommendation.